Amcor Completes One-for-Five Reverse Stock Split

Rhea-AI Summary

Amcor (NYSE: AMCR) completed a 1-for-5 reverse stock split, effective with trading on a split-adjusted basis on January 16, 2026.

The split was approved by shareholders on November 6, 2025, and the memorandum of association amendment was filed on January 14, 2026. Amcor ordinary shares continue trading under AMCR on the NYSE with a new CUSIP G0250X149. CHESS Depositary Interests continue trading under AMC on a split-adjusted basis. Computershare is acting as exchange agent; registered U.S. shareholders and CDI holders have specified contact numbers for exchange questions. More details are available in Amcor's September 23, 2025 proxy and on its investor website.

Positive

• Completed a 1-for-5 reverse split effective Jan 16, 2026
• New NYSE CUSIP G0250X149 established for ordinary shares

Negative

• Shares consolidated at a 1-for-5 ratio, which may reduce share count
• Potentially lower liquidity due to split-adjusted trading (immediate effect)

Key Figures

Chromium Xo price: $25,000 Cell capture rate: 80% Gene sensitivity uplift: 40% +2 more

5 metrics

Chromium Xo price $25,000 U.S. list price for single cell instrument

Cell capture rate 80% GEM-X 3' assay maximum cell capture

Gene sensitivity uplift 40% Higher gene sensitivity vs non-10x methods

Sequencing cost savings 50% Potential savings vs non-10x methods

Target cost per sample $100 Goal for high-performance single cell analysis per sample

Market Reality Check

Price: $21.20 Vol: Volume 20,290,336 is slig...

normal vol

$21.20 Last Close

Volume Volume 20,290,336 is slightly above the 20-day average of 17,582,218. normal

Technical Trading near its 200-day MA at 8.8, indicating a largely trend-aligned position pre-split.

Peers on Argus

Peers show mixed moves: positives for PKG, BALL, AVY and negatives for SW, IP. N...

Peers show mixed moves: positives for PKG, BALL, AVY and negatives for SW, IP. No momentum scanner confirmation of a coordinated sector move.

Historical Context

5 past events · Latest: Dec 11 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 11	Reverse split plan	Neutral	-1.2%	Announced timing and mechanics of 1-for-5 reverse stock split.
Nov 18	Innovation initiative	Positive	+0.1%	Launched Lift-Off challenge to source sustainable packaging technologies.
Nov 05	Quarterly earnings	Positive	+2.5%	Reported strong Q1 growth, synergies and reaffirmed fiscal 2026 guidance.
Oct 27	Sustainability report	Positive	+1.6%	Released FY25 sustainability metrics showing progress on circularity and emissions.
Oct 22	Earnings scheduling	Neutral	+1.1%	Announced timing and access details for Q1 2026 results call.

Pattern Detected

Recent news with clearly positive fundamentals (earnings, sustainability progress) saw modestly positive price reactions, while the earlier reverse split announcement drew a small decline.

Recent Company History

Over the last few months, Amcor reported strong combined Q1 results with $5,745M net sales and $909M adjusted EBITDA, reaffirmed fiscal 2026 guidance, and raised its quarterly dividend. Sustainability reporting highlighted progress on circularity, emissions and recyclability, while innovation programs like Amcor Lift-Off targeted more sustainable packaging technologies. The prior 1-for-5 reverse split announcement on Dec 11, 2025 produced a modest -1.2% move, providing the key historical reference for today’s reverse split completion.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-15

The company has an active S-3ASR shelf registration dated 2025-07-15, effective through 2028-07-15, with 0 recorded usages to date. This provides pre-cleared flexibility to issue securities if the company chooses, but no usage has been disclosed in the provided data.

Market Pulse Summary

This announcement completes Amcor’s previously outlined 1-for-5 reverse stock split, following share...

Analysis

This announcement completes Amcor’s previously outlined 1-for-5 reverse stock split, following shareholder approval and the effective date set in December 2025. It is a largely mechanical step that consolidates shares while leaving recent fundamentals—such as strong Q1 results and reaffirmed fiscal 2026 guidance—unchanged. Investors may focus on how split-adjusted metrics are reported, any impacts on trading liquidity, and how this action fits alongside the company’s existing S-3ASR flexibility and recent governance decisions.

Key Terms

single cell analysis, spatial biology, sequencing, ffpe

4 terms

single cell analysis medical

"Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis."

A laboratory method that examines individual cells one by one to measure their genes, proteins or activity, rather than averaging results across many cells. For investors, it matters because this fine-grained view can reveal hidden subpopulations, pinpoint more precise drug targets, improve diagnostic tests and reduce development risk—think of inspecting each brick in a wall to find the ones that need repair instead of judging the wall as a whole.

spatial biology medical

"10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo,"

Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.

sequencing technical

"GEM-X technology also enables researchers to generate more usable reads to detect more genes with less sequencing, potentially saving more than 50% on sequencing costs"

Sequencing is the laboratory process that reads the exact order of the building blocks in DNA or RNA, like reading the letters in a book that make up a living organism’s instruction manual. For investors, sequencing matters because it powers diagnostics, drug discovery and personalized medicine — similar to how having a detailed map lets a company target opportunities more precisely, which can change revenue potential and regulatory risk.

ffpe medical

"upgrade to Chromium X to access the full breadth of the company's single cell portfolio, including assays for FFPE samples and immune profiling."

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

AI-generated analysis. Not financial advice.

ZURICH, Jan. 15, 2026 /PRNewswire/ -- Amcor plc (NYSE: AMCR; ASX: AMC), a global leader in developing and producing responsible packaging solutions, announced today it has completed its previously announced 1-for-5 reverse stock split.

The reverse stock split was approved by Amcor shareholders at its annual general meeting of shareholders held on November 6, 2025.  Amcor filed an amendment to its memorandum of association to effect the reverse stock split on January 14, 2026.

Amcor ordinary shares began trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") today and shares continue to trade under the symbol "AMCR" with a new CUSIP number, which is G0250X 149.  Amcor's CHESS Depositary Interests ("CDIs") continue to trade under the symbol "AMC" and are also now trading on a split-adjusted basis.

Amcor's transfer agent, Computershare, is acting as exchange agent for the reverse stock split. Registered U.S. shareholders who hold their shares directly may contact Computershare toll free at 1-866-526-3029 (within the U.S.), or at 1-617-668-3920.  Holders of CDIs may contact Computershare toll free at 1300 850 505 (within Australia) or at +61 3 9415 4000 (outside of Australia).  If you hold your shares with a broker, queries should be directed to your broker.

Additional information concerning the reverse stock split can be found in Amcor's definitive proxy statement filed with the Securities and Exchange Commission on September 23, 2025, as well as on Amcor's Investor Relations website, https://www.amcor.com/investors.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons, and closures, that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC

www.amcor.com  I  LinkedIn  I  YouTube

FAQ

What did Amcor (AMCR) announce about a reverse stock split on January 16, 2026?

Amcor completed a 1-for-5 reverse stock split; shares began trading split-adjusted on Jan 16, 2026.

When was the Amcor (AMCR) reverse split approved by shareholders?

Shareholders approved the 1-for-5 reverse split at the annual meeting on November 6, 2025.

Did Amcor change its CUSIP after the reverse split and what is it?

Yes; Amcor ordinary shares now trade under CUSIP G0250X149 on the NYSE.

Are Amcor CHESS Depositary Interests (AMC) affected by the reverse split?

Yes; CHESS Depositary Interests continue trading under AMC and are now split-adjusted.

Who is the exchange agent for Amcor's reverse stock split and how can shareholders contact them?

Computershare is acting as exchange agent; U.S. registered shareholders can call 1-866-526-3029 or 1-617-668-3920.